Gout

• 

  Subject Areas on Research

  • 2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. 
  • 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. 
  • A histopathologic study of retinal arterial aneurysms. 
  • A natural experiment in the quality of care in gout. 
  • A reappraisal of the concept of an abnormality of glutamine metabolism in primary gout. 
  • Acute gout presenting in the manubriosternal joint. 
  • Agency and structure in the sociology of sickness. 
  • An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. 
  • Antihypertensive effectiveness of very low doses of hydrochlorothiazide: results of the PHICOG Trial. 
  • Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls. 
  • Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease. 
  • Biochemical profile of stone-forming patients with diabetes mellitus. 
  • Cardiovascular Disease Prevalence in Patients with Osteoarthritis, Gout, or Both. 
  • CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. 
  • Circulating galectin-3 in infections and non-infectious inflammatory diseases. 
  • Clinical Images: a not-so crystal-clear ankle mass. 
  • Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. 
  • Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation. 
  • Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. 
  • Colchicine--Update on mechanisms of action and therapeutic uses. 
  • Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking. 
  • Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. 
  • Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. 
  • Decreased colorectal atypia among a cohort of gout patients. 
  • Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. 
  • Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target? 
  • Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. 
  • Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. 
  • Erosive spinal tophus in a patient with gout and back pain. 
  • Ethnic background has minimal impact on the etiology of nephrolithiasis. 
  • Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy. 
  • Familial hyperuricemia and renal insufficiency. 
  • Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study. 
  • Febuxostat: a new agent for lowering serum urate. 
  • Fine-needle aspiration cytology of articular and periarticular lesions. 
  • Genetics of hyperuricemia and gout: implications for the present and future. 
  • Gout and its comorbidities. 
  • Gout and the regulation of purine biosynthesis. 
  • Gout as a source of sesamoid pain. 
  • Gout management: let's get it right this time. 
  • Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. 
  • Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? 
  • Gout, tophi and the wonders of NETs. 
  • Gout: no longer the disease of kings. 
  • Hyperuricemia, gout, and cardiovascular disease--an important "muddle". 
  • Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. 
  • Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. 
  • Inpatient gout: a review. 
  • Intermediary purine metabolism and the metabolic defects of gout. 
  • Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). 
  • Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. 
  • Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. 
  • Long-term colchicine administration leading to colchicine toxicity and death. 
  • Long-term safety of pegloticase in chronic gout refractory to conventional treatment. 
  • Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function. 
  • Migration and gout: the Tokelau Island migrant study. 
  • Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients. 
  • Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis? 
  • New and Pipeline Drugs for Gout. 
  • Normal glycine-C14-incorporation into uric acid in primary gout. 
  • OMERACT endorsement of measures of outcome for studies of acute gout. 
  • On the mechanism of overproduction of uric acid in patients with primary gout. 
  • Overproduction of uric acid as the cause of hyperuricemia in primary gout. 
  • Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout. 
  • Pegloticase for treating refractory chronic gout. 
  • Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. 
  • Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. 
  • Plasma glutamine and oxypurine content in patients with gout. 
  • Prevalence of contraindications and prescription of pharmacologic therapies for gout. 
  • Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion. 
  • Progress in the pharmacotherapy of gout. 
  • Quality of life and disability in patients with treatment-failure gout. 
  • Reassessing serum urate targets in the management of refractory gout: can you go too low? 
  • Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. 
  • Refractory gout: what is it and what to do about it? 
  • Renal calculi: pathogenesis, diagnosis, and medical therapy. 
  • Rheumatologic manifestations of cancer. 
  • Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. 
  • Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. 
  • Safety of urate-lowering therapies: managing the risks to gain the benefits. 
  • Saturnine gout, redux: a review. 
  • The current state of care in gout: Addressing the need for better understanding of an ancient disease. 
  • The kinetics of intramolecular distribution of 15N in uric acid after administration of (15N) glycine. A reappraisal of the significance of preferential labeling of N-(3+9) of uric acid in primary gout. 
  • The kinetics of intramolecular distribution of 15N in uric acid following administration of 15N-glycine: preferential labeling of N-(3+9) of uric acid in primary gout and a reappraisal of the "glutamine hypothesis". 
  • The rheumatology of gout. 
  • The role of the kidney in the pathogenesis and treatment of gout. 
  • Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. 
  • Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. 
  • Unusual clinical presentations of gout. 
  • Update on the management of hyperuricemia and gout. 
  • Uricase and other novel agents for the management of patients with treatment-failure gout. 
  • Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. 
• 

  Keywords of People

  • Allen, Nancy Bates, Professor of Medicine, Medicine, Rheumatology and Immunology
  • Ostbye, Truls, Professor of Family Medicine and Community Health, Family Medicine and Community Health
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery